Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5'-nucleotidase in myeloid leukocytes.
The expression of P2 purinergic receptor subtypes in leukocytes varies with both lineage and developmental stage. Given the recent identification and cloning of at least seven distinct G protein-coupled ATP receptor subtypes (P2Y family), we investigated P2Y receptor subtype expression during myeloid cell differentiation. We observed that KG-1 myeloblasts express P2Y1 but not P2Y2 receptors (previously termed P2U receptors), whereas later myeloid progenitors, including HL-60 promyelocytes and THP-1 monocytes, expressed P2Y2 but not P2Y1 receptors. In KG-1 cells, significant activation of Ca2+ mobilization by P2Y1 receptors was only observed after preincubation with potato apyrase, an exogenous ATPase. This indicated that P2Y1 receptors are desensitized in KG-1 cells by autocrine mechanisms that may involve enhanced release of endogenous nucleotides and/or decreased expression of cell-surface ecto-nucleotidases. We compared the levels of ecto-apyrase activity and expression in KG-1 myeloblasts and HL-60 promyelocytes. Extracellular ATP was rapidly metabolized by HL-60 but not by KG-1 cells. Reverse transcription-polymerase chain reaction analysis indicated that mRNA for CD39 (cluster of differentiation), an identified ecto-apyrase, was present in HL-60 but not KG-1 cells. Ecto-apyrase activity was modestly increased with differentiation of myeloid progenitors with either phorbol 12-myristate 13-acetate (PMA) or dibutyryl adenosine 3',5'-cyclic monophosphate (DBcAMP). Differentiation of HL-60 cells with PMA, but not DBcAMP, strongly induced ecto-5'-nucleotidase activity and CD73 mRNA expression. These observations indicate that signal transduction by extracellular ATP in myeloid leukocytes can be regulated by developmentally programmed changes in the expression of P2Y receptor subtypes and multiple ecto-nucleotidases.
Clifford
E E
EE
Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4970, USA.
Martin
K A
KA
Dalal
P
P
Thomas
R
R
Dubyak
G R
GR
D015720:5'-Nucleotidase / Q000096:biosynthesis*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000249:Adenosine Monophosphate / Q000494:pharmacology; D000251:Adenosine Triphosphatases; D000255:Adenosine Triphosphate / Q000494:pharmacology; D015703:Antigens, CD / Q000096:biosynthesis*; D001081:Apyrase / Q000096:biosynthesis*; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000502:physiology; D003600:Cytosol / Q000187:drug effects / Q000378:metabolism; D017931:DNA Primers; D015972:Gene Expression Regulation, Neoplastic; D018922:HL-60 Cells / Q000378:metabolism; D006801:Humans; D007938:Leukemia; D007962:Leukocytes / Q000378:metabolism*; D008954:Models, Biological; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger; D018048:Receptors, Purinergic P2 / Q000096:biosynthesis*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014544:Uridine Triphosphate / Q000494:pharmacology
D015703:Antigens, CD; D017931:DNA Primers; D012333:RNA, Messenger; D018048:Receptors, Purinergic P2; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D003994:Bucladesine; D000255:Adenosine Triphosphate; D015720:5'-Nucleotidase; D000251:Adenosine Triphosphatases; D001081:Apyrase; C067869:CD39 antigen; D013755:Tetradecanoylphorbol Acetate; D014544:Uridine Triphosphate